Photo by aaronburden from unsplash
α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB‐312 is a synthetic αSyn peptide conjugated to… Click to show full abstract
α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB‐312 is a synthetic αSyn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligomeric and fibrillar αSyn, making UB‐312 a potential immunotherapeutic for synucleopathies.
Keywords:
randomized first;
study 312;
peptide;
312 ubith;
human study;
first human
Journal Title: Movement Disorders
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Movement Disorders
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!